TABLE 2.

Excluded patients in analysis (N = 65).

Reason for exclusion	n
Pre–weight maintenance phase/treatment
Generic second‐generation AOMs in MWLB only (no GLP‐1 RA use)	7
MWLB (with GLP‐1 RA use) ended early	4
MWLB (with GLP‐1 RA use) not completed yet	25
Subgroup 1 total	36
Weight maintenance phase
GLP‐1 RA use in MWLB, then continued GLP‐1 RA therapy (n = 9 T2DM; n = 3 cash‐pay option)	12
GLP‐1 RA use in MWLB, but no generic AOMs prescribed	17
Subgroup 2 total	29
Total subgroup 1 + subgroup 2	65

Note: 105 patients in MWLB who achieved BMI <30 kg/m² at 12 mo after enrollment were identified. Only patients who completed 12 mo of therapy and transitioned to older‐generation generic AOMs were included in the data analysis in this study (n = 40). These patients were placed on oral metformin, topiramate, bupropion, naltrexone monotherapy, or combination; phentermine was avoided in many cases due to its controlled substance designation upon transition to primary care.

Abbreviations: AOM, antiobesity medication; GLP‐1 RA, glucagon‐like peptide‐1 receptor agonist; MWLB, medical weight loss bundle; T2DM, type 2 diabetes mellitus.